香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 臨時股東會之表決結果 茲提述中國同輻股份有限公司（「本公司」）日期為2025年12月18日的本公司2026 年第一次臨時股東會通告（「臨時股東會通告」）。除文義另有所指外，本公告所用 詞彙與臨時股東會通告所界定者具有相同涵義。 董事會欣然宣佈於2026年1月9日（星期五）上午十時正假座中國北京市海淀區廠窪 中街66號4層403室舉行的臨時股東會之投票結果。臨時股東會依照中國公司法及 本公司公司章程的規定合法有效召開，由董事長肖亞飛先生主持。根據《香港聯 合交易所有限公司證券上市規則》（「上市規則」）之規定，臨時股東會通告所載之 決議案以投票方式表決。 | | 普通決議案 | | 投票數目及佔投票總數的概約百分比 | | | --- | -- ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國同輻股份有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01763 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 79,968,800 | RMB | | 1 RMB | | 79,968,800 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 79,968,800 | RMB | | 1 RMB | | 79,968,800 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類 ...

2025年12月31日，原子高科也披露了子公司海得威补税事项。原子高科方面表示，预计上述事项将影响 公司2025年度归母净利润为0.54亿元。 中经记者 晏国文 卢志坤 北京报道 2025年上半年，中国同辐营业收入为28.58亿元，同比增长1.7%；净利润为3.41亿元，同比增长11.2%。 海得威2024年营业收入为23.54亿元，净利润为5.26亿元。 2025年12月31日，港股上市公司中国同辐（1763.HK）披露，旗下非全资附属公司深圳市中核海得威生 物科技有限公司（以下简称"海得威"）近日补缴2024年企业所得税、增值税等1.88亿元及滞纳金，合计 为2.71亿元。 中国同辐方面称，该事项将影响中国同辐2025年利润约1.3亿元。 （编辑：曹学平 审核：童海华 校对：翟军） ...

智通财经APP讯，中国同辐(01763)发布公告，于2025年12月31日，经相关主管机关认定，公司非全资附 属公司深圳市中核海得威生物科技有限公司(海得威)近日应补缴2021年1月1日至2024年12月31日企业所 得税、增值税等税款人民币1.88亿元及滞纳金合计人民币2.71亿元，主要涉及海得威前述年度期间的销 售费用、存货非正常损失等，该事项不涉及行政处罚。截至本公告日期，海得威已完成该税款缴纳。预 期该涉税事项将影响2025年度的权益股东应占年内利润约人民币1.30亿元，但与该结付有关的实际财务 影响将视公司独立核数师的审阅及审核结果而定。 此外，公司对上述事项高度重视，将进一步提高自身的管理能力，切实维护公司及股东利益。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資 者，於2025年12月31日，經相關主管機關認定，本公司之非全資附屬公司深圳 市中核海得威生物科技有限公司（「海得威」）近日應補繳2021年1月1日至2024年 12月31日企業所得稅、增值稅等稅款人民幣1.88億元及滯納金合計人民幣2.71億 元，主要涉及海得威前述年度期間的銷售費用、存貨非正常損失等，該事項不涉 及行政處罰。 截至本公告日期，海得威已完成該稅款繳納。預期該涉稅事項將影響2025年度的 權益股東應佔年內利潤約人民幣1.30億元，惟與該結付有關的實際財務影響將視 乎本公司獨立核數師的審閱及審核結果而定。 本公司對上述事項高度重視，將進一步提高自身的管理能力，切實維護公司 ...

Market Overview - The Hong Kong stock market experienced fluctuations on December 22, with the Hang Seng Index rising by 0.43% to close at 25,801.77 points, the Hang Seng Tech Index increasing by 0.87% to 5,526.83 points, and the National Enterprises Index up by 0.43% to 8,939.68 points [1] - Major technology stocks showed mixed performance, with Alibaba up by 0.76%, Tencent Holdings up by 0.08%, and JD Group up by 0.9%, while Xiaomi fell by 1.83% and NetEase by 0.09% [1] - The optical communication sector was strong, with Huiju Technology rising by 13% and Changfei Optical Fiber Cable up by 11% [1] - Duty-free concept leader China Duty Free Group surged over 15%, while the new consumption sector saw significant gains, with Mixue Group up over 10% and Pop Mart up over 4% [1] - Chip stocks also rose, with SMIC increasing by nearly 6% and Hua Hong Semiconductor up over 5% [1] - Gold stocks generally rose, with China National Gold up over 7% and Shandong Gold up over 5% [1] - Four new stocks were listed, including Impression Dahongpao and Huacheng Biotechnology, all of which experienced a decline in their initial trading [1] Company News - SF Holding reported a total revenue of 27.173 billion yuan for November, a year-on-year increase of 7.85%, with express logistics revenue growing by 9.88% and business volume increasing by 20.13% [2] - Capital Venture expects to achieve an unaudited net profit of approximately 115 million to 140 million HKD for the fiscal year ending September 30, 2025, marking a turnaround from losses, primarily due to improved performance in listed equity investments [2] - Tianqi Lithium announced the completion of the third phase of its chemical-grade lithium concentrate expansion project, which has officially commenced trial production [3] - Qingdao Port plans to purchase two assets from the cruise port development for the Qingdao Shipping Financial Center [4] - CanSino Biologics has initiated Phase I clinical trials for its DTCP–HIb–MCV4 combined vaccine, completing the enrollment of the first subject [5] - Junshi Biosciences received FDA approval for the Phase I clinical trial application of its biosimilar HLX18 for the treatment of various solid tumors [5] - China National Nuclear Corporation's subsidiary, CNNC Haidewei, received clinical approval for its BNCT boron drug [6] - Hisense Home Appliances subscribed to a financial product from Jingu Trust worth 1.892 billion yuan [7] - Evergrande Property's liquidator has received several updated non-binding offers from selected bidders, which are currently under consideration [7] - Ruian Construction completed the sale of Ruian Property Management Services [8] - Tianjin Port Development's subsidiary plans to purchase ten gantry cranes for 185 million yuan [9] Institutional Insights - CITIC Securities noted that after a strong rally in September, the Hong Kong market has experienced fluctuations since October due to varying overseas macro expectations, with quality assets becoming more attractive [10] - Huatai Securities indicated that the market is still in a left-side layout phase, with uncertainties surrounding the "Santa rally" and potential supply-demand pressures at year-end [10] - China Galaxy suggested focusing on the technology sector as a long-term investment theme, which has seen valuation corrections and may rebound due to multiple favorable factors [10] - The consumption sector is expected to receive significant policy support, with current valuations at relatively low levels, indicating potential for long-term growth [10]

Company News - SF Holding (06936.HK) reported a total revenue of 27.173 billion yuan for its express logistics, supply chain, and international business in November, representing a year-on-year growth of 7.85%. The express logistics business revenue grew by 9.88%, with a business volume increase of 20.13% [2] - Capital Investment (02324.HK) expects to achieve an unaudited consolidated net profit of approximately 115 million to 140 million HKD for the fiscal year ending September 30, 2025, marking a turnaround from losses, primarily due to the performance of listed equity investments [2] - Tianqi Lithium (09696.HK) has completed the construction of the third phase of its chemical-grade lithium concentrate expansion project and has officially commenced trial production [2] - Qingdao Port (06198.HK) plans to purchase two assets from the Qingdao Shipping Financial Center for the development of a cruise port [2] - CanSino Biologics (06185.HK) has initiated Phase I clinical trials for its DTCP–HIb–MCV4 combined vaccine and completed the enrollment of the first subject [2] - Fuhong Hanlin (02696.HK) received approval from the U.S. Food and Drug Administration for its application for the Phase I clinical trial of HLX18, a biosimilar to Nivolumab for the treatment of various solid tumors [2] - China National Nuclear Corporation (01763.HK) announced that its subsidiary, CNNC Haidewei, has received clinical approval for its BNCT boron drug [2] - Hisense Home Appliances (00921.HK) subscribed to a financial product from Jingu Trust for 1.892 billion yuan [2] Acquisition and Disposal - Evergrande Property (06666.HK) has received several updated non-binding offers from selected bidders, which the liquidators are currently considering [3] - Ruian Construction (00983.HK) has completed the sale of Ruian Property Management Services Co., Ltd. [4] - Tianjin Port Development (03382.HK) plans to purchase ten gantry cranes for 185 million yuan [5] Buyback Activities - Tencent Holdings (00700.HK) repurchased 1.036 million shares at a cost of 636 million HKD, with buyback prices ranging from 607 to 617 HKD [5] - Xiaomi Group-W (01810.HK) repurchased 3.75 million shares for 152 million HKD, with buyback prices between 40.42 and 40.56 HKD [6] - COSCO Shipping Holdings (01919.HK) repurchased 3.9655 million shares for 53.6689 million HKD, with buyback prices ranging from 13.47 to 13.73 HKD [6] - Kuaishou-W (01024.HK) repurchased 755,000 shares for 49.9509 million HKD, with buyback prices between 65.4 and 66.6 HKD [7]

中国同辐(01763)发布公告，近日，国家药品监督管理局药品审评中心(CDE)官网信息显示公司附属公司 深圳市中核海得威生物科技有限公司(中核海得威)自主研发的2.2类改良新药"注射用硼[10B]法 仑"(BNCT硼药：硼中子俘获疗法，Boron neutron capture therapy)临床试验申请获批(通知书编号： 2025LP03425)。 中核海得威自研的国产"注射用硼[10B]法仑"针对对放化疗不敏感、复发性、难治性、浸润性、中晚 期、局部转移的头颈部肿瘤具有显著临床优势，且治疗疗程短(仅需1-2次)、毒副作用低，代表了现代肿 瘤精准医学的发展方向和前沿创新，为患者提供了全新的治疗选择，推动了肿瘤治疗领域的创新与突 破。 此外，中核海得威"注射用硼[10B]法仑"临床试验申请获批标志着中核海得威BNCT药械协同研发领域取 得突破性成果，正式迈入临床转化新阶段，为"健康中国"战略下的精准肿瘤治疗注入核科技新动能，为 全球肿瘤治疗贡献"中国方案"。 ...

智通财经APP讯，中国同辐(01763)发布公告，近日，国家药品监督管理局药品审评中心(CDE)官网信息 显示公司附属公司深圳市中核海得威生物科技有限公司(中核海得威)自主研发的2.2类改良新药"注射用 硼[B]法仑"(BNCT硼药：硼中子俘获疗法，Boron neutron capture therapy)临床试验申请获批(通知书编 号：2025LP03425)。 此外，中核海得威"注射用硼[B]法仑"临床试验申请获批标志着中核海得威BNCT药械协同研发领域取得 突破性成果，正式迈入临床转化新阶段，为"健康中国"战略下的精准肿瘤治疗注入核科技新动能，为全 球肿瘤治疗贡献"中国方案"。 中核海得威自研的国产"注射用硼[B]法仑"针对对放化疗不敏感、复发性、难治性、浸润性、中晚期、 局部转移的头颈部肿瘤具有显著临床优势，且治疗疗程短(仅需1-2次)、毒副作用低，代表了现代肿瘤精 准医学的发展方向和前沿创新，为患者提供了全新的治疗选择，推动了肿瘤治疗领域的创新与突破。 ...

中核海得威「注射用硼[10B]法仑」临床试验申请获批标志着中核海得威BNCT药械协同研发领域取得突 破性成果，正式迈入临床转化新阶段，为「健康中国」战略下的精准肿瘤治疗注入核科技新动能，为全 球肿瘤治疗贡献「中国方案」。 中核海得威自研的国产「注射用硼[10B]法仑」针对对放化疗不敏感、复发性、难治性、浸润性、中晚 期、局部转移的头颈部肿瘤具有显着临床优势，且治疗疗程短(仅需1-2次)、毒副作用低，代表了现代肿 瘤精准医学的发展方向和前沿创新，为患者提供了全新的治疗选择，推动了肿瘤治疗领域的创新与突 破。 格隆汇12月19日丨中国同辐(01763.HK)宣布，近日，国家药品监督管理局药品审评中心(CDE)官网信息 显示公司附属公司深圳市中核海得威生物科技有限公司「中核海得威」自主研发的2.2类改良新药「注 射用硼[10B]法仑」(BNCT硼药：硼中子俘获疗法，Boronneutroncapturetherapy)临床试验申请获批(通知 书编号：2025LP03425)。 ...